<DOC>
	<DOCNO>NCT02524951</DOCNO>
	<brief_summary>This Phase I , open-label , dose escalation study . MSI-1436 administer single intravenous infusion twice week 3 week 4-week cycle .</brief_summary>
	<brief_title>Safety Tolerability MSI-1436C Metastatic Breast Cancer</brief_title>
	<detailed_description>This Phase I , open-label , dose escalation study . MSI-1436 administer single intravenous infusion twice week 3 week 4-week cycle . Subjects enrol accord standard Phase I Fibonacci design receive MSI-1436 . Drug infusion last approximately 2 hour . If subject dose-limiting toxicity ( DLT ) time study , MSI-1436 hold either re-started discontinued subject per Dose Adjustments Toxicities Guidelines .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Signed , witness , date Institutional Review Board ( IRB ) approve Informed Consent Form ( ICF ) . Pathologically confirm metastatic breast cancer measurable disease . Metastatic site must measurable CT , MRI , FDGPET/CT per revise RECIST v1.1 criterion measurable disease physical examination . A metastatic site must biopsy proven Life expectancy ≥3 month . Patients enrol must receive 2 line therapy patient HER2 express tumor must receive HER2 targeted therapy . Female Age ≥18 year . Stable brain metastasis permit . This consider measurable disease . Stable brain metastasis define change CT scan MRI minimum 2 month AND change steroid dose minimum 4 week A negative serum pregnancy test , female reproductive potential . Reproductive potential define age &lt; 55 menses &lt; 1 year Screening laboratory value follow : Total bilirubin ≤1.5 time upper limit normal ( ULN ) . Aspartate aminotransferase ( serum glutamic oxaloacetic transaminase ) alanine aminotransferase ( serum glutamic pyruvate transaminase ) ≤ 2.5 time ULN . Serum creatinine ≤2.0 mg/dL calculate creatinine clearance ≥60 mL/min . Absolute neutrophil count &gt; 1,500 cells/mm3 . Platelet count ≥100,000 plt/mm3 . Hemoglobin ≥ 8 g/dL . Nondiabetic Pregnant breastfeeding ECOG Performance Status great 2</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>